Steven H. Bernstein, MD joined The Mark Foundation as its Chief Medical Officer in February 2018. He also serves as the Senior Vice President for Clinical Research and Development at Turnstone Biologics. Previously, Dr. Bernstein served as Chair, Immuno-Oncology Translational Research and Development, and Head, Integrated Science at Bristol Myers Squibb. Dr. Bernstein has more than 20 years of experience as an academic physician at both Roswell Park Cancer Institute and most recently at the University of Rochester’s James P. Wilmot Cancer Institute, where he was Professor of Medicine and Oncology, Co-director of both the Hematological Malignancy Program and the Lymphoma Biology Program and Co-Principal Investigator of the University of Rochester/University of Arizona NCI Specialized Programs of Research Excellence (SPORE) Grant in Lymphoma. Dr. Bernstein maintained an active clinical practice caring for patients suffering from lymphoproliferative disorders, while engaging in both clinical and translational research as the Principal Investigator of a funded laboratory program in lymphoma immunobiology and developmental therapeutics. Dr. Bernstein was a member of the Lymphoma Working Group of SWOG, the Scientific Advisory Board of the Lymphoma Research Foundation, the Executive Committee of the International Mantle Cell Lymphoma Consortium and the Scientific and Medical Advisory Board of the Leukemia and Lymphoma Society. Dr. Bernstein received his MD degree from New York University School of Medicine followed by residency, fellowship and post-doctoral studies at the University of Chicago, NYU/Bellevue Hospital, Boston’s Beth Israel Deaconess Medical Center, and the Dana-Farber Cancer Institute.